Neuropeptide S vs Dulaglutide
Head-to-head comparison of Neuropeptide S (Neuropeptide S) and Dulaglutide (Recombinant GLP-1 receptor agonist Fc fusion protein) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Neuropeptide S | Dulaglutide |
|---|---|---|
| Category | Cognitive Enhancement | Weight Management |
| Full Name | Neuropeptide S | Recombinant GLP-1 receptor agonist Fc fusion protein |
| Molecular Weight | 2203 Da | ~63,000 Da |
| Half-Life | Minutes to <1 hour | About 5 days |
| Amino Acids | 20 | N/A |
| Typical Dose | Research-only; no validated human dose | 0.75-4.5 mg weekly |
| Route | Intracerebroventricular/Intranasal | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 28 | 700 |
| Research Status | Pre-clinical | Approved |
Neuropeptide S Benefits
- ✓anxiolysis
- ✓stress resilience
- ✓attention support
- ✓arousal modulation
Dulaglutide Benefits
- ✓modest weight loss
- ✓lower A1c
- ✓weekly dosing convenience
- ✓cardiometabolic benefit
Neuropeptide S Dosing
0.1-1 nmol i.c.v. in animal studies|intranasal research-only exploration|no established human protocol
Dulaglutide Dosing
0.75-4.5 mg SC weekly|Increase based on response and tolerance|Administer on the same day each week
Neuropeptide S Side Effects
- ⚠sleep disruption
- ⚠headache
- ⚠jitteriness
Dulaglutide Side Effects
- ⚠nausea
- ⚠diarrhea
- ⚠injection-site reactions
Research Overview
Neuropeptide S
Animal studies suggest NPS can reduce anxiety-like behavior while altering wakefulness and alertness through the NPS receptor system. Human cognitive data are very limited, and it has no approved clinical indication.
Dulaglutide
Dulaglutide has repeatedly shown small-to-moderate reductions in body weight alongside glycemic improvement in large diabetes trials. It is a useful comparator for GLP-1 receptor agonist effects on appetite and weight.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.